Don’t miss a new episode

The Second Word in Digital Transformation

Don’t miss a new episode

1X
0:00|–:–

McKinsey puts the failure rate for digital transformation initiatives at 70% across industries — projects that don’t meet their stated objectives. Pharma’s regulated environment makes the path harder, not easier. 

In this episode of Pharma Talks, Paul Tunnah — founder of Pharmaphorum, healthcare communications expert, and co-founder of View AI — argues that most of those failures are preventable, and that the preventable part isn’t technical. 

He opened by objecting to the framing itself: 

I feel a bit allergic to the word digital. People get obsessed with technology, channels, and all that, but transformation is broader. It’s about people and how companies operate. 

The Word That Gets Ignored 

The first word in “digital transformation” points at technology. The second points at people — and it’s where the work actually happens: how ways of working change, how mindsets shift, what skills get built. 

Which explains the pattern of organizations adopting innovation without sustaining it. Enormous effort goes into selecting and implementing a technology ecosystem; the people component becomes an afterthought. 

Teams resist when they don’t see the value, don’t understand the context, or lack support. When global and local aren’t aligned, the change reads as a top-down decision that made the work different without making it better. 

The root of it is a sequencing error. Discussions start with technology — shiny tool syndrome, where attention goes to selecting platforms before anyone has defined the problem. The order that works: understand what change is required, then determine how technology supports it. Talking about models, copilots, and automation without a clear picture of how they help teams work better doesn’t produce anything. 

Caution Has Its Own Cost 

Concerns about AI security and compliance are legitimate, and ignoring them would be irresponsible. 

But focusing exclusively on them produces its own outcome — inaction that eventually creates the exposure it was avoiding. 

There’s risk when adopting any new technology, but there’s also a reward. If AI helps solve a problem in collaboration with people, the upside is huge. 

His reminder for conservative organizations: “If your competitors are adopting new technologies and you’re not, that’s a risk too.” 

The workable version is responsible adoption with cross-functional ownership. Decisions about what to share with AI models and what to protect shouldn’t sit with one function. 

It’s about understanding what’s unique to your company versus what’s generic. These decisions should involve IT and business leaders together, because they understand both security and downstream application. 

Evolution, Not Revolution 

AI coverage arrives with a visual grammar of disruption — blue screens, robotic hands, futuristic imagery — which reinforces an expectation that adoption happens fast. 

Asked whether AI in CRM and customer engagement is revolution or evolution, Paul didn’t hesitate: “I’d say evolution. Technology moves fast, but data, workflows, and people take time. Systemic change is gradual.” 

Expecting entrenched habits to shift quickly isn’t impossible so much as improbable. What produces results is continuous change management that embeds technology into real workflows and gives teams a reason to use it. 

He describes the resulting state as perpetual beta — tools evolving, processes adapting, organizations learning continuously. His practical conclusion from that: “Big companies shouldn’t try to build bespoke systems. It’s better to partner with experts who are constantly improving the tools.” 

The Data Problem Is Abundance 

Looking toward 2026, Paul’s read on engagement is that people are already saturated. Companies respond by adding channels when the constraint is quality, relevance, and trust. 

The assumption underneath most personalization efforts is that data is scarce. Usually the opposite is true. Customer feedback, social listening, real-world evidence, years of engagement history — it’s already there, and gathering it into one place is where the difficulty becomes visible rather than where it resolves. 

Personas aren’t static. Start with segments, optimize dynamically, and make sure field reps have the right materials to engage effectively. 

The analogy that follows is apt: a clinician interprets complex data to guide one patient. Field teams need the same kind of structured guidance to adapt content to the interaction actually in front of them. 

Feedback, Not Dashboards 

Effective engagement looks effortless and almost never is. Nataliya’s example was the amount of preparation hidden behind anything that appears simple. 

Paul connected it to how ecosystems should be built: 

Our ecosystems must provide feedback. Learn and adapt. Dashboards alone aren’t enough. And don’t get lost in big data. Maintain the human connection. 

Hot or Not 

Short prompts, quick reads on where things are heading: 

Generative AI producing 70% of pharma content — “Not yet. People factor still matters.” 

Commercial and medical teams building content together — “Hot. It’s happening.” 

Hyperpersonalization versus strong segmentation — “Hot. Fix segments first before chasing n equals one personalization.” 

Replacing channel mix thinking with story architecture — “Hot. Focus on story, not just channels.” 

Final Reflection 

Transformation is a change in how teams think, work, and learn. AI is the tool that supports it, and as the technology matures it will become more capable and less visible — working in the background the way a good interpreter does, enabling the conversation without becoming part of it. 

The condition Paul returns to throughout: it only sticks when it makes sense to the people doing the work, and to the people the work is meant to serve.

Subscribe

To Get Pharma Talks Episodes Straight To Your Inbox.

     

    We use the details you submit to review your application and to contact you about appearing on PharmaTalks. If we go ahead, we will agree the terms of the recording with you separately, including the permissions we need to publish the episode. See the Privacy Policy for how we handle your data and the rights you have.

     

     

    FAQ

    What is Pharma Talks about?
    Pharma Talks is a pharma podcast where industry leaders discuss life sciences, commercialization, tech adoption, digital transformation, and leadership. 
    Who are Pharma Talks for?
    This pharma marketing podcast is for life sciences professionals, pharma leaders, marketers, medical teams, and innovators who want to grow and refuse to accept the industry status quo. 
    Who is the Pharma Talks host? 
    This pharmaceutical podcast is hosted by Nataliya Andreychuk, founder and CEO of Viseven, a global company that helps life sciences brands reach HCPs and patients faster with compliant and impactful content. She is also a LinkedIn voice in the industry, a member of the Forbes Agency Council, and a frequent speaker at industry events. Nataliya brings more than 20 years of experience in marketing and life sciences. 
    Can I become a guest at Pharma Talks?
    If you have experience in pharma and life sciences or have founded a brand, platform, or media, you can apply to be a guest and share your story with our audience.